Information  X 
Enter a valid email address

Omega Diagnostics Gp (ODX)


Tuesday 08 June, 2021

Omega Diagnostics Gp

Regulatory progress for VISITECT® COVID-19 test

RNS Number : 0850B
Omega Diagnostics Group PLC
08 June 2021


("Omega" or the "Company" or the "Group")


Regulatory progress for VISITECT® COVID-19 Antigen test


Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance, provides the following update on VISITECT® COVID-19 Antigen test regulatory approvals.


Regulatory approvals

Omega announces that it has begun the process of engagement with its European Notified Body seeking CE marking of the VISITECT® COVID-19 Antigen test, a rapid point-of-care diagnostic test for the detection of active COVID-19 infections as a self-test. The Company is agreeing the protocols required for utilisation studies and will update shareholders as this process progresses. The test is already CE marked for professional-use and the Company is targeting approval by the end of July to allow the test to be sold in Europe for home-use as well. As the global market for Antigen testing develops the Company believes self-test approval will be a key product differentiator, as has already been seen in the UK.


The Company also announces that its technology partner, Mologic Ltd ("Mologic") has successfully completed the necessary performance studies required for regulatory approval in the US and is now in the final stages of preparing a submission to the U.S. Food and Drug Administration (FDA) requesting Emergency Use Authorization (EUA) for its rapid point-of-care COVID-19 antigen test, for use under both the Omega's VISITECT® brand and Global Access Diagnostics brand.


Colin King, CEO of Omega, commented: 

"I am pleased with the progress we are making to gain regulatory approval, both for our VISITECT self-test product and for US professional use. Both routes offer potentially significant opportunities as we believe we have a high quality product with global appeal."




Omega Diagnostics Group PLC

Colin King, Chief Executive

via Walbrook PR

Kieron Harbinson, Group Finance Director

finnCap Ltd

Tel: 020 7220 0500

Geoff Nash/Edward Whiley (Corporate Finance)

Alice Lane (ECM)

Walbrook PR Limited

Tel: 020 7933 8780 or [email protected]

Paul McManus

Mob: 07980 541 893

Lianne Cawthorne

Mob: 07584 391 303




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

a d v e r t i s e m e n t